Literature DB >> 16036419

New ideas for therapy in ALS.

Michael Swash.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16036419     DOI： 10.1080/14660820510035379

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN： 1466-0822


× No keyword cloud information.
  4 in total

1.  The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.

Authors:  Maithao N Le; Joseph L-K Chan; Stephen A Rosenberg; Adam S Nabatian; Kim T Merrigan; Karine A Cohen-Solal; James S Goydos
Journal:  J Invest Dermatol       Date:  2010-05-27       Impact factor: 8.551

Review 2.  The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.

Authors:  SubbaRao V Madhunapantula; Paul J Mosca; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

3.  A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.

Authors:  Dana Yip; Maithao N Le; Joseph L-K Chan; Jonathan H Lee; Janice A Mehnert; Anthony Yudd; Jeffery Kempf; Weichung J Shih; Suzie Chen; James S Goydos
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

4.  Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.

Authors:  Yu Wen; Jiadong Li; Jasmine Koo; Seung-Shick Shin; Yong Lin; Byeong-Seon Jeong; Janice M Mehnert; Suzie Chen; Karine A Cohen-Sola; James S Goydos
Journal:  Cancer Res       Date:  2014-02-03       Impact factor: 12.701
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.